BRAF V600E mutation mediates FDG-methionine uptake mismatch in polymorphous low-grade neuroepithelial tumor of the young
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-5960
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
BRAF V600E mutation mediates FDG-methionine uptake mismatch in polymorphous low-grade neuroepithelial tumor of the young ; volume:8 ; number:1 ; day:18 ; month:8 ; year:2020 ; pages:1-8 ; date:12.2020
Acta Neuropathologica Communications ; 8, Heft 1 (18.8.2020), 1-8, 12.2020
- Urheber
-
Tateishi, Kensuke
Ikegaya, Naoki
Udaka, Naoko
Sasame, Jo
Hayashi, Takahiro
Miyake, Yohei
Okabe, Tetsuhiko
Minamimoto, Ryogo
Murata, Hidetoshi
Utsunomiya, Daisuke
Yamanaka, Shoji
Yamamoto, Tetsuya
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40478-020-01023-3
- URN
-
urn:nbn:de:101:1-2020100923230232141831
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:58 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Tateishi, Kensuke
- Ikegaya, Naoki
- Udaka, Naoko
- Sasame, Jo
- Hayashi, Takahiro
- Miyake, Yohei
- Okabe, Tetsuhiko
- Minamimoto, Ryogo
- Murata, Hidetoshi
- Utsunomiya, Daisuke
- Yamanaka, Shoji
- Yamamoto, Tetsuya
- SpringerLink (Online service)
Ähnliche Objekte (12)
Early molecular diagnosis of BRAF status drives the neurosurgical management in BRAF V600E-mutant pediatric low-grade gliomas: a case report
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie
Loss of Phd2 cooperates with BRAF V600E to drive melanomagenesis
BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature
BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer
Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF V600E metastatic colorectal cancer
Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
Frequency of BRAF V600E mutations in 969 central nervous system neoplasms
BRAF V600E-Positive Multisite Langerhans Cell Histiocytosis in a Preterm Neonate
BRAF-V600E-Testung beim metastasierten kolorektalen Karzinom und neue, chemotherapiefreie Therapieoptionen
Early molecular diagnosis of BRAF status drives the neurosurgical management in BRAF V600E-mutant pediatric low-grade gliomas: a case report
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie
Loss of Phd2 cooperates with BRAF V600E to drive melanomagenesis
BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature
BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer
Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF V600E metastatic colorectal cancer
Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
Frequency of BRAF V600E mutations in 969 central nervous system neoplasms
BRAF V600E-Positive Multisite Langerhans Cell Histiocytosis in a Preterm Neonate
BRAF-V600E-Testung beim metastasierten kolorektalen Karzinom und neue, chemotherapiefreie Therapieoptionen
Early molecular diagnosis of BRAF status drives the neurosurgical management in BRAF V600E-mutant pediatric low-grade gliomas: a case report
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie
Loss of Phd2 cooperates with BRAF V600E to drive melanomagenesis
BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature
BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer
Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF V600E metastatic colorectal cancer
Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
Frequency of BRAF V600E mutations in 969 central nervous system neoplasms
BRAF V600E-Positive Multisite Langerhans Cell Histiocytosis in a Preterm Neonate